CA-JUNIPER-NETWORKS
Juniper Networks , (NYSE: JNPR) a leader in secure, AI-driven networks, announced today that CMC Networks, a global service provider offering market-leading networking solutions, is the first Juniper partner to offer a managed AI-driven SD-WAN solution in Africa. A dynamic and self-optimizing network will deliver a superior experience to CMC’s customers, allowing them to easily modify their services, add new locations and spin up and down network speeds. Time-to-market is significantly reduced, enabling CMC to provision services faster.
By leveraging Juniper’s unique Session Smart® Router technology driven by Mist AI, CMC is delivering a unique tunnelless solution that is designed for scale and agility, coupled with automated provisioning, management and troubleshooting for maximum uptime, superior performance of real-time traffic and lower operating costs in both rural and urban environments.
News highlights:
- CMC chose the Session Smart Router and standardized on Juniper’s STEP (Service and Topology Exchange Protocol) in order to navigate network traffic with real-time data information. This allows accurate and immediate decision making autonomously, minimizing delays to ensure that network traffic arrives at its destination in the most efficient way possible. This helps to ensure that CMC’s customers receive a SD-WAN service that is high-performing, secure and reliable.
- The Juniper solution includes Secure Vector Routing (SVR), a transformational new intelligent routing architecture that enables CMC’s network to differentiate the way it delivers applications and services to end users. The SVR allows a network to identify problems and automatically decide the most effective path to re-route traffic. This supports business applications without user intervention, in support of the best possible user experience.
- The Juniper® Session Smart Router (SSR) fuels an advanced, service-centric networking solution and Mist AI engine that takes software-defined routing and SD-WAN to a new level. The SSR enables agile, secure, and resilient WAN connectivity. With tunnelless SSR technology, each session is secured with zero trust access by default, providing the highest level of security. Additionally, eliminating tunnel overhead increases bandwidth capacity and enables an improved user experience.
- CMC has been rolling out Session Smart Routers in Africa for the last three years, leveraging the organization’s scale and footprint to enable digital transformation across the region. In the future, the company plans to broaden its footprint into additional regions and deliver even more AI-driven managed services powered by Juniper, including wireless access.
- CMC is in the process of planning the rollout of additional cloud-hosted services driven by Mist AI, including WAN Assurance and the Marvis™ Virtual Network Assistant . These further streamline the deployment, operations and troubleshooting of its AI-driven SD-WAN environment with zero touch provisioning, customizable service levels, self-driving operations and AI-driven support to proactively address problems before customers even know they exist.
Supporting Quotes:
“SD-WAN is not a new technology and every SD-WAN player gives customers speed and power on the network. However, digital transformation strategies require a high level of intelligence, support and the ability to underpin business-critical applications - attributes that many SD-WAN vendors can’t provide. Juniper’s AI-driven SD-WAN gives CMC a level of intelligence and operational insight that we haven’t seen before.”
Geoff Dornan, Chief Technology Officer, CMC Networks
"Juniper’s AI-driven SD-WAN solution, powered by our Session Smart Router and Mist AI, enables us to be laser-focused on optimizing user experience. We recognized early that networks must be application-aware to support the demands of the evolving enterprise and to deliver the highest levels of user experience. Juniper ticks all the necessary boxes by delivering on the promise of a truly intelligent network that adapts as user requirements change. Juniper is thrilled that our innovative work with CMC has yielded this much-needed solution to enable consistent and excellent user experiences, even in the most challenging geographies, and we look forward to continued collaboration."
Sue Graham Johnston, Vice President and General Manager, Juniper Networks
Additional Resources:
CMC Networks: Connecting African & Middle Eastern Communities with Secure, Reliable SD-WAN (video)
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net ) or connect with Juniper on Twitter , LinkedIn and Facebook .
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
Category-Service Provider
View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005023/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
